Trial Profile

A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vorolanib (Primary) ; Aflibercept
Indications Wet age-related macular degeneration
Focus Registrational; Therapeutic Use
Acronyms LUGANO
Sponsors EyePoint

Most Recent Events

02 Sep 2026 According to an EyePoint media release, clinical data from this trial will be presented at The Retina Society 59th Annual Scientific Meeting from September 23-26, 2026, in Los Angeles, CA.
17 Aug 2026 According to an EyePoint media release, company will host a conference call today, August 17, 2026, at 8:00 a.m. EDT to discuss the LUGANO topline results.
17 Aug 2026 Results presented in the EyePoint media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com